Greater Manchester

Cardiovascular research domain

The Cardiovascular Domain applies discovery and translational science, and excellence in clinical care, to improve life expectancy for patients with cardiovascular disease in Greater Manchester.

Greater Manchester is one of the largest population catchments for tertiary cardiac services in Europe and offers a unique resource for clinical research. This is also combined with training the next generation of healthcare staff and researchers to the highest standard. Through the strengths and catchment populations of our partners, we will take early discovery and innovation from basic underpinning research into practice, prove effectiveness, and disseminate best practice across our region.

Greater Manchester’s population suffers disproportionately from heart and circulatory disease. Our services include large tertiary cardiac units (Central Manchester University Hospitals NHS Foundation Trust and University Hospital of South Manchester) that, together, provide the highest quality specialist care to a population of around 3.5 million people, with additional provision of nationally designated cardiopulmonary transplantation and ventricular assist services to 6.6 million people.

Stroke is a devastating condition affecting people of all ages, causing death and long-term disability. Following changes to GM hospital stroke services in 2015 to ensure patients have access to better quality hospital care and timely specialist treatment, Greater Manchester now has the best scoring hospital stroke pathway in the country, with all stroke patients having access to care rated as ‘A’ (the highest available rating) by The Sentinel Stroke National Audit Programme. Stroke research is an important part of stroke services and a major research strength in Manchester. A wide range of studies involving stroke and the emergency conditions affecting the brain, take place at Salford Royal NHS Foundation Trust.

The University of Manchester’s Division of Cardiovascular Sciences combines clinical, translational and basic science research with the aim of translating our understanding of the cellular and molecular processes underlying cardiovascular disease into improved clinical treatments and patient care.

We focus on three research areas: Hypertension and its consequences; Cardiac physiology and heart failure; and Cardiovascular Genomics. These research strengths are interdisciplinary, feature strong international collaborations and address global cardiovascular health challenges. The university’s Division of Diabetes, Endocrinology and Metabolism comprises internationally leading researchers into endocrine organ development, diabetic complications, the neuronal control of appetite, and circadian clocks in cardiometabolic disease.

In addition, the disease burden on North West England is particularly high for common diseases such as diabetes. Our successful research programmes aim to improve the screening and treatment of this disease.


Pioneering research in Manchester established the role of interleukin-1 in mediating neurological damage  following stroke in animal models, and showed that IL-1 receptor antagonism could reduce damage.

Internationally renowned cellular cardiac physiologists in Manchester are researching basic mechanisms of arrhythmogenesis in animal models and in human tissue samples provided by MAHSC partners.

Back to top